P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product

Drug Metabolism and Disposition

Volumn 24, Issue 6, 1996, Pages 649-654

  Kharasch, Evan D ^a   Hankins, Douglas C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIFLUORO 1 (TRIFLUOROMETHYL)VINYL FLUOROMETHYL ETHER; 4 METHYLPYRAZOLE; COUMARIN; CYTOCHROME P450; DIETHYLTHIOCARBAMATE; DRUG METABOLITE; ORPHENADRINE; SEVOFLURANE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEFLUORINATION; DRUG DEGRADATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; NEPHROTOXICITY; PRIORITY JOURNAL;

ANESTHETICS, INHALATION; CYTOCHROME P-450 CYP2E1; ETHERS; FLUORIDES; HUMANS; HYDROCARBONS, FLUORINATED; METHYL ETHERS; MICROSOMES, LIVER; NADP;

EID: 0029999323     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. R. F. Wallin, B. M. Regan, M. D. Napoli, and I. J. Stern: Sevoflurane: a new inhalational anesthetic agent. Anesth. Analg. 54, 758-766 (1975).
2. C. Hanaki, K. Fujii, M. Morio, and T. Tashima: Decomposition of sevoflurane by soda lime. Hiroshima J. Med. Sci. 36, 61-67 (1987).
3. 2 absorbents during low-flow anesthesia in surgical patients. Anesthesiology 77, 1064-1069 (1992).
4. H. Bito and K. Ikeda: Closed-circuit anesthesia with sevoflurane in humans: Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology 80, 71-76 (1994).
5. H. Bito and K. Ikeda: Long-duration, low-flow sevoflurane anesthesia in humans using two carbon dioxide absorbents. Anesthesiology 81, 340-345 (1994).
6. E. J. Frink Jr., R. J. Isner, T. P. Malan Jr., S. Morgan, E. A. Brown, and B. R. Brown Jr.: Sevoflurane degradation product concentrations with soda lime during prolonged anesthesia. J. Clin. Anesth. 6, 239-242 (1994).
7. M. Mono, K. Fujii, N. Satoh, M. Imai, U. Kawakami, T. Mizuno, Y. Kawai, Y. Ogasawara, T. Tamura, A. Negishi, Y. Kumagai, and T. Kawai: Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology 77, 1155-1164 (1992).
8. C. T. Gonsowski, M. J. Laster, E. I. Eger II, L. D. Ferrell, and R. L. Kerschmann: Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 80, 566-573 (1994).
9. C. T. Gonsowski, M. J. Laster, E. I. Eger II, L. D. Ferrell, and R. L. Kerschmann: Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology 80, 556-565 (1994).
10. K. A. Keller, C. Callan, P. Prokocimer, M. S. Delgado-Herrera, M. B. Friedman, G. M. Hoffman, W. L. Wooding, P. K. Cusick, and R. W. Krasula. Inhalation toxicology study of a haloalkene degradant of sevoflurane. Compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 83, 1220-1232 (1995).
11. 2 absorbents during low-flow sevoflurane anesthesia in surgical patients. J. Anesth. 9, 1-5 (1995).
12. H. Bito and K. Ikeda: Plasma inorganic fluoride and intracircuit degradation product concentrations in long-duration, low-flow sevoflurane anesthesia. Anesth. Analg. 79, 946-951 (1994).
13. R.I. Mazze: The safety of sevoflurane in humans. Anesthesiology 77, 1062-1063 (1992).
14. L. Jin, T. A. Baillie, M. R. Davis, and E. D. Kharasch: Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) in rats: Evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase. Biochem. Biophys. Res Commun. 210, 498-506 (1995).
15. K. E. Thummel, E. D. Kharasch, T. Podoll, and K. Kunze: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21, 350-357 (1993).
16. E. D. Kharasch and K. E. Thummel: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79, 795-807 (1993).
17. R. I. Mazze: Fluorinated anaesthetic nephrotoxicity: An update. Can. Anaesth. Soc. J. 31, S16-S22 (1984).
18. E. D. Kharasch, D. C. Hankins, and K. E. Thummel: Human kidney methoxyflurane and sevoflurane metabolism: intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82, 689-699 (1995).
19. G. F. Reidy, I. Mehta, and M. Murray: Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol. Pharmacol. 35, 736-743 (1989).
20. M. Mimura, T. Baba, H. Yamazaki, S. Ohmori, Y. Inui, F. J. Gonzalez, F. P. Guengerich, and T. Shimada: Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056 (1993).
21. H. Yamazaki, Y. Inui, C.-H. Yun, F. P. Guengerich, and T. Shimada: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789-1794 (1992).
22. L. Jin, M. R. Davis, E. D. Kharasch, G. A. Doss, and T. A. Baillie: Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agenl sevoflurane. Chem. Res. Toxicol. 9, 555-561 (1996).
23. D. A. Holaday and R. England: Deuteration reduced significantly the biotransformation of sevoflurane. Anesthesiology 57, A246 (abstr.) (1982).
24. M. T. Baker, W. C. Ronnenberg, J. A. Ruzicka, C. -K. Chiang, and J. H. Tinker: Inhibitory effects of deuterium substitution on the metabolism of sevoflurane. Drug Metab. Dispos. 21, 1170-1171 (1993).
25. J. Hoffman, K. Konopka, C. Buckhorn, D. R. Koop, and L. Waskell: Ethanol-inducible cytochrome P450 in rabbits metabolizes enflurane. Br. J. Anaesth. 63, 103-108 (1989).
26. E. D. Kharasch, A. S. Armstrong, K. Gunn, A. Artru, and K. Cox: Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 82, 1379-1388 (1995).
27. R. I. Mazze, M. J. Cousins, and J. C. Kosek: Strain differences in metabolism and susceptibility to the nephrotoxic effects of methoxyflurane in rats. J. Pharmacol. Exp. Ther. 184, 481-488 (1973).
28. G. L. Kennedy Jr.: Toxicology of fluorine-containing monomers. Crit. Rev. Toxicol. 21, 149-170 (1990).